Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 4 7Phase 3 4Phase 2/3 3Phase 2 2Phase 1/2 1

Status

Completed 4Unknown 3Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Pain, Postoperative 2Neoplasms 1Inflammation 1Agnosia 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Dexmedetomidine × Clear all
NCT05340725 2023-01-23

DEX-NANO

Assiut University

Phase 2/3 Unknown
45 enrolled

Pain, Postoperative

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown
20 enrolled

Inflammation, Neoplasms

NCT02455609 2015-05-28

Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain

Assiut University

Phase 2/3 Unknown
90 enrolled

Agnosia, Pain, Postoperative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡